Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether his Department has had recent discussions with Eli Lilly on the cost of Mounjaro.

The Department has held various discussions with Eli Lilly regarding the recent list price increase of Mounjaro. NHS England has worked with Eli Lilly to ensure the list price increase will not affect National Health Service commissioning of tirzepatide in England as a treatment for eligible diabetes and obesity patients in the NHS.

We remain committed to the rollout of this medicine as a weight loss treatment based on clinical priority. This will enable 220,000 eligible people to access the medication over the first three years. The initial eligibility criteria will be for people with a body mass index of 40 or more in addition to four or more qualifying comorbidities.

Scotland, Wales and Northern Ireland have also entered equivalent agreements to maintain their current commissioning approaches.

Pricing in the private market is a matter for Eli Lilly and for private providers. Private patients who are impacted by price increases should discuss any concerns with their private provider. This includes their options regarding payment plans, alternative treatments, and/or stopping or tapering off their current medication. Eli Lilly is working with private providers to support continued patient access.